Aeglea BioTherapeutics Investor Presentation Deck slide image

Aeglea BioTherapeutics Investor Presentation Deck

SPY002 clones are unique in binding both monomers and trimers with picomolar potency SUPERIOR MONOMER AND TRIMER BINDING¹ Greater monomer binding (M) 10-⁹. 10-10. NO MONOMER BINDING 10-10 SPYRE RVT-3101 TEV-48574 SELECT SPYRE CLONES MK-7240 Greater trimer binding (M) Source: Nonclinical data on file. 1Compared to TEV-48574, RVT-3101, MK-7240 10-⁹ SUPERIOR TF-1 APOPTOSIS INHIBITION¹ 100- %Inhibition TF-1 Apoptosis 50 0₁ 0.01 HAHH TOTECHO EN H H TEV-48574 RVT-3101 MK-7240 SELECT SPYRE CLONES 0.1 1 10 Antibody Concentration (nM) 100 23
View entire presentation